Genovn Therapeutics

Genovn Therapeutics is a clinical-stage biotechnology company based in Hangzhou, China, dedicated to the development of transformative gene therapies for rare and life-threatening diseases. The company leverages a proprietary adeno-associated virus (AAV) vector platform to design and manufacture high-potency genetic medicines. Its lead program, EXG001-034, is currently in clinical trials for the treatment of Spinal Muscular Atrophy (SMA), aiming to provide a durable therapeutic effect through a single administration. Beyond neuromuscular disorders, Genovn is expanding its pipeline into ophthalmology and metabolic conditions, including treatments for wet age-related macular degeneration. The company is supported by prominent life science investors and maintains integrated capabilities from early-stage R&D to GMP manufacturing.